Last week's biggest biotech story: Cytokinetics hit both dual primary endpoints in the ACACIA-HCM pivotal Phase 3 trial of aficamten in non-obstructive hypertrophic cardiomyopathy — the first cardiac myosin inhibitor to win in nHCM and a major franchise expansion. Moderna's mRNA-1010 flu vaccine also landed in NEJM, and DDW 2026 drove a cluster of IBD readouts.

This week we cover:

1. Cytokinetics ($CYTK) — aficamten for non-obstructive hypertrophic cardiomyopathy (Phase 3)

2. Moderna ($MRNA) — mRNA-1010 seasonal influenza vaccine (Phase 3)

3. Avalo Therapeutics ($AVTX) — abdakibart (AVTX-009) for hidradenitis suppurativa (Phase 2)

4. Viridian Therapeutics ($VRDN) — elegrobart for chronic thyroid eye disease (Phase 3)

5. Johnson & Johnson ($JNJ) — JNJ-4804 (guselkumab + golimumab) for refractory ulcerative colitis and Crohn's disease (Phase 2b)

6. Bayer ($BAYRY) — asundexian for secondary stroke prevention (Phase 3 OCEANIC-STROKE late-breaking)

7. AbbVie ($ABBV) — risankizumab (Skyrizi) and upadacitinib (Rinvoq) long-term IBD data (Phase 3)

8. Eli Lilly ($LLY) — mirikizumab (Omvoh) long-term IBD data (Phase 3)

9. Nuance Pharma (private) — nafithromycin (MIQNAF) for community-acquired bacterial pneumonia (Phase 3)

10. Bioxodes (private) — BIOX-101 for intracerebral hemorrhage (Phase 2a)

The Cytokinetics nHCM win opens up a second indication for aficamten and pressures BMS's Camzyos directly, while Moderna's NEJM publication strengthens its bid for FDA approval and a seasonal flu commercial launch. DDW 2026 was a watershed for combination biologic IBD therapy.

Subscribe for weekly clinical trial breakdowns at TrialBreaks.com

#biotech #clinicaltrials #pharma #cardiology #HCM #obesity #vaccines #mRNA #immunology #IBD #ulcerativecolitis #Crohns #neurology #stroke #dermatology #hidradenitis #thyroideyedisease #infectiousdisease